Interferon-β modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients

Abstract

Purpose Multiple sclerosis (MS) patients have a high risk of low bone density. The purpose of this study was to examine the molecular mechanisms potentially capable of modulating bone home-ostasis in response to interferon-β-1a (IFN-β-1a) treatment and the focus was the bone-modulating system comprised of receptor activator of nuclear factor-κB (RANK), its ligand RANKL and its decoy receptor, osteoprotegerin (OPG).

Methods In this open-label pharmacodynamic study, peripheral blood was obtained from relapsing remitting MS patients just prior to and at multiple time points after intramuscular injection of 30 μg IFN-β-1a. Samples were analysed for RANKL, tumour necrosis factor related apoptosis-inducing ligand (TRAIL), OPG and macrophage inflammatory protein-1α/β expression. Osteoclast precursor differentiation from peripheral blood cells of MS patients in the presence of exogenously added IFN-β-1a was also assessed. Additionally, the changes in plasma levels of osteocalcin and the C-telopeptides after 1 year of treatment were measured as surrogate markers of bone formation and degradation, respectively.

Results IFN-β-1a treatment modulated RANKL and OPG in a selective, time-dependent manner. The levels of OPG protein decreased 25% at the 8-h time point, then increased 43% at the 24-h time point. The levels of free RANKL reached a maximum at the 8-h time point. Increases in the levels of macrophage inflammatory protein-1β (MIP-1β), a chemokine that increases osteolysis, were observed. The levels of the bone formation marker, osteocalcin, were lower in MS patients compared to controls and increased after one year of treatment. Ex vivo treatment of peripheral blood lymphocytes with IFN-β resulted in a marked reduction of osteoclast-like cells in the presence of RANKL and macrophage colony stimulating factor.

Conclusions IFN-β treatment induces complex, specific and time-dependent changes in multiple proteins and mRNAs related to bone homeostasis in MS patients.

Keywords

bone gene expression interferons multiple sclerosis osteoporosis pharmacodynamics

Get full access to this article

View all access options for this article.

References

Weinstock-Guttman B , Gallagher E , Baier M , Green L , Feichter J , Patrick K et al. Risk of bone loss in men with multiple sclerosis . Mult Scler 2004; 10: 170-175 .

Nieves J , Cosman F , Herbert J , Shen V , Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis . Neurology 1994; 44: 1687-1692 .

Cosman F , Nieves J , Komar L , Ferrer G , Herbert J , Formica C et al. Fracture history and bone loss in patients with MS . Neurology 1998; 51: 1161-1165 .

The IFNB Multiple Sclerosis Study Group . Inter-feron beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group . Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Ann Neurol 1996; 39: 285-294 .

Theill LE , Boyle WJ , Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution . Annu Rev Immunol 2002; 20: 795-823 .

Shipman CM , Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells . Cancer Res 2003; 63: 912-916 .

Gong B , Almasan A. Genomic organization and transcriptional regulation of human Apo2/TRAIL gene . Biochem Biophys Res Commun 2000; 278: 747-752 .

10.

Wandinger KP , Lunemann JD , Wengert O , Bell-mann-Strobl J , Aktas O , Weber A et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis . Lancet 2003; 361: 2036-2043 .

11.

Takayanagi H , Kim S , Matsuo K , Suzuki H , Suzuki T , Sato K et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta . Nature 2002; 416: 744-749 .

12.

Takayanagi H , Ogasawara K , Hida S , Chiba T , Murata S , Sato K et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma . Nature 2000; 408: 600-605 .

13.

Takayanagi H , Kim S , Taniguchi T. Signaling crosstalk between RANKL and interferons in osteoclast differentiation . Arthritis Res 2002; 4: S227-S232 .

14.

Huang JC , Sakata T , Pfleger LL , Bencsik M , Halloran BP , Bikle DD et al. PTH differentially regulates expression of RANKL and OPG . J Bone Miner Res 2004; 19: 235-244 .

15.

Lindberg MK , Erlandsson M , Alatalo SL , Windahl S , Andersson G , Halleen JM et al. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum inter-leukin-6 in male mice . J Endocrinol 2001; 171: 425-433 .

16.

Hayashi T , Kaneda T , Toyama Y , Kumegawa M , Hakeda Y. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs-in IFN-beta-inhibited osteoclast formation . J Biol Chem 2002; 277: 27880-27886 .

17.

Ritchlin CT , Haas-Smith SA , Li P , Hicks DG , Schwarz EM. Mechanisms of TNF-alpha- and RANKL- mediated osteoclastogenesis and bone resorption in psoriatic arthritis . J Clin Invest 2003; 111: 821-831 .

18.

Hartrich L , Weinstock-Guttman B , Hall D , Badgett D , Baier M , Patrick K et al. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients . J Neuroimmunol 2003; 139: 84-92 .

19.

Ducy P , Amling M , Takeda S , Priemel M , Schilling AF , Beil FT et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass . Cell 2000; 100: 197-207 .

20.

Katagiri T , Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation . Oral Dis 2002; 8: 147-159 .

21.

Zhang M , Xuan S , Bouxsein ML , von Stechow D , Akeno N , Faugere MC et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization . J Biol Chem 2002; 277: 44005-44012 .

22.

Abe M , Hiura K , Wilde J , Moriyama K , Hashimoto T , Ozaki S et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma . Blood 2002; 100: 2195-2202 .

23.

Choi SJ , Cruz JC , Craig F , Chung H , Devlin RD , Roodman GD et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma . Blood 2000; 96: 671-675 .

24.

Han JH , Choi SJ , Kurihara N , Koide M , Oba Y , Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand . Blood 2001; 97: 3349-3353 .

25.

Giuliani N , Colla S , Sala R , Moroni M , Lazzaretti M , La Monica S et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease . Blood 2002; 100: 4615-4621 .

26.

Giuliani N , Colla S , Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL) . Exp Hematol 2004; 32: 685-691 .

27.

Misu T , Onodera H , Fujihara K , Matsushima K , Yoshie O , Okita N et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling . J Neuroimmunol 2001; 114: 207-212 .

28.

Balashov KE , Rottman JB , Weiner HL , Hancock WW. CCR5(/) and CXCR3(/) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions . Proc Natl Acad Sci U S A 1999; 96: 6873-6878 .

29.

Simpson J , Rezaie P , Newcombe J , Cuzner ML , Male D , Woodroofe MN. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue . J Neuroimmunol 2000; 108: 192-200 .

30.

Strunk T , Bubel S , Mascher B , Schlenke P , Kirchner H , Wandinger KP. Increased numbers of CCR5/interferon-gamma- and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients . Ann Neurol 2000; 47: 269-273 .

31.

Trebst C , Sorensen TL , Kivisakk P , Cathcart MK , Hesselgesser J , Horuk R et al. CCR1+/CCR5+mono-nuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis . Am J Pathol 2001; 159: 1701-1710 .

32.

Knott L , Bailey AJ. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance . Bone 1998; 22: 181-187 .

33.

Garnero P , Hausherr E , Chapuy MC , Marcelli C , Grandjean H , Muller C et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study . J Bone Miner Res 1996; 11: 1531-1538 .

34.

Garnero P , Shih WJ , Gineyts E , Karpf DB , Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment . J Clin Endocrinol Metab 1994; 79: 1693-1700 .

35.

Greenspan SL , Parker RA , Ferguson L , Rosen HN , Maitland-Ramsey L , Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial . J Bone Miner Res 1998; 13: 1431-1438 .

36.

Gertz BJ , Shao P , Hanson DA , Quan H , Harris ST , Genant HK et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine . J Bone Miner Res 1994; 9: 135-142 .

37.

Chaki O , Yoshikata I , Kikuchi R , Nakayama M , Uchiyama Y , Hirahara F et al. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women . J Bone Miner Res 2000; 15: 1537-1544 .

38.

Delmas PD , Schlemmer A , Gineyts E , Riis B , Christiansen C. Urinary excretion of pyridinoline cross-links correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis . J Bone Miner Res 1991; 6: 639-644 .

39.

Noronha A , Toscas A , Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis . J Neuroimmunol 1993; 46: 145-153 .

40.

Rudick RA , Carpenter CS , Cookfair DL , Tuohy VK , Ransohoff RM. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant inter-feron beta . Neurology 1993; 43: 2080-2087 .

41.

Gayo A , Mozo L , Suarez A , Tunon A , Lahoz C , Gutierrez C. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS [see comments] . Neurology 1999; 52: 1764-1770 .

42.

Munafo A , Trinchard-Lugan II , Nguyen TX , Buraglio M. Comparative pharmacokinetics and pharmaco-dynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration . Eur J Neurol 1998; 5: 187-193 .

43.

Buchwalder PA , Buclin T , Trinchard I , Munafo A , Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers . J Interferon Cytokine Res 2000; 20: 857-866 .

44.

Pettit AR , Ji H , von Stechow D , Muller R , Goldring SR , Choi Y et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis . Am J Pathol 2001; 159: 1689-1699 .

45.

Li J , Sarosi I , Yan XQ , Morony S , Capparelli C , Tan HL et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism . Proc Natl Acad Sci USA 2000; 97: 1566-1571 .

46.

Bucay N , Sarosi I , Dunstan CR , Morony S , Tarpley J , Capparelli C et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification . Genes Dev 1998; 12: 1260-1268 .

47.

Dorner BG , Scheffold A , Rolph MS , Huser MB , Kaufmann SH , Radbruch A et al. MIP-1alpha, MIP- 1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines . Proc Natl Acad Sci U S A 2002; 99: 6181-6186 .

48.

Wandinger KP , Sturzebecher CS , Bielekova B , Detore G , Rosenwald A , Staudt LM et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes . Ann Neurol 2001; 50: 349-357 .

49.

Weinstock-Guttman B , Badgett D , Patrick K , Hartrich L , Santos R , Hall D et al. Genomic effects of IFN-beta in multiple sclerosis patients . J Immunol 2003; 171: 2694-2702 .

50.

de Veer MJ , Holko M , Frevel M , Walker E , Der S , Paranjape JM et al. Functional classification of inter-feron-stimulated genes identified using microarrays . J Leukoc Biol 2001; 69: 912-920 .

51.

Perez Castrillon JL , Cano-del Pozo M , Sanz-Izquierdo S , Velayos-Jimenez J , Dib-Wobakin W. [Bone mineral density in patients with multiple sclerosis: the effects of interferon] . Rev Neurol 2003; 36: 901-903 .

52.

Stenager E , Jensen K. Fractures in multiple sclerosis . Acta Neurol Belg 1991; 91: 296-302 .

53.

Schlaich C , Minne HW , Bruckner T , Wagner G , Gebest HJ , Grunze M et al. Reduced pulmonary function in patients with spinal osteoporotic fractures . Osteoporos Int 1998; 8: 261-267 .